316 related articles for article (PubMed ID: 33212301)
1. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.
Miyazaki Y; Fujiwara H; Asai H; Ochi F; Ochi T; Azuma T; Ishida T; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2013 Jun; 121(24):4894-901. PubMed ID: 23641014
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).
Maggadóttir SM; Kvalheim G; Wernhoff P; Sæbøe-Larssen S; Revheim ME; Josefsen D; Wälchli S; Helland Å; Inderberg EM
Front Oncol; 2022; 12():1031232. PubMed ID: 36439452
[TBL] [Abstract][Full Text] [Related]
5. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
7. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
Purbhoo MA; Li Y; Sutton DH; Brewer JE; Gostick E; Bossi G; Laugel B; Moysey R; Baston E; Liddy N; Cameron B; Bennett AD; Ashfield R; Milicic A; Price DA; Classon BJ; Sewell AK; Jakobsen BK
Mol Cancer Ther; 2007 Jul; 6(7):2081-91. PubMed ID: 17620437
[TBL] [Abstract][Full Text] [Related]
8. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
10. A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.
Lanitis E; Smith JB; Dangaj D; Flingai S; Poussin M; Xu S; Czerniecki BJ; Li YF; Robbins PF; Powell DJ
Hum Gene Ther; 2014 Aug; 25(8):730-9. PubMed ID: 25003657
[TBL] [Abstract][Full Text] [Related]
11. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
12. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
13. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
Ayyoub M; Migliaccio M; Guillaume P; Liénard D; Cerottini JC; Romero P; Lévy F; Speiser DE; Valmori D
Eur J Immunol; 2001 Sep; 31(9):2642-51. PubMed ID: 11536162
[TBL] [Abstract][Full Text] [Related]
14. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
16. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
[TBL] [Abstract][Full Text] [Related]
19. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
20. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
